
|Videos|November 14, 2020
AAO: Study confirms Phase III results for uveitis treatment
Author(s)OTE Staff Reports
Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.
Advertisement
Glenn J. Jaffe, MD, presents a summary of the results of a confirmatory study on a previous Phase III trial that examined sustained drug delivery for the treatment of uveitis, as well as data on the 36-month results in the second, confirmatory phase 3 study of YUTIQ.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
Lumvoa gains US FDA approval for thyroid eye disease with class-first broad label
2
European Dry Eye Society Congress 2026: real-world evidence on Artelac Complete in dry eye disease
3
DEX implant shows benefit across RVO subgroups in real-world retrospective study
4
Q&A: Uveitis risk rises as immune checkpoint inhibitor use expands
5

























